- Brand names:
- Pharmaceutical Company:
- Condition/Indication:
- Meeting Date: November 2018
- Public Summary Document (PSD) November 2018 PBAC Meeting - PDF
- Public Summary Document (PSD) November 2018 PBAC Meeting - Word
Durvalumab – November 2018
Durvalumab: Solution for I.V. infusion 120 mg in 2.4 mL, Solution for I.V. infusion 500 mg in 10 mL;
Last updated
15 March 2019
